Shares surged 4.2% to $406.39 after Amgen posted second-quarter results that blew past Wall Street expectations on every major line, then raised full-year guidance — a move that forces investors to weigh accelerating drug sales against a towering balance sheet.
The Beat Was Decisive, Not Marginal
Adjusted earnings hit $6.29 per share, topping the $5.62 consensus by 12%.
Revenue climbed 10% to $10.05 billion versus analyst estimates of $9.43 billion, with product sales up 9% to $9.54 billion on pure volume growth. This wasn't pricing power or one-time items — it was more patients on more drugs, the kind of organic growth that supports durable earnings.
Twenty-Two Drugs Pulling Their Weight Cushions the Blow From Aging Blockbusters
Twenty-two products delivered at least double-digit sales growth in the quarter.
Cholesterol drug Repatha rose 37% to $953 million, bone-building treatment Evenity jumped 38% to $714 million, rare-disease therapy Uplizna surged 90% to $335 million, and cancer drug Imdelltra grew 115% to $288 million. That breadth matters because Prolia and XGEVA — two older mainstays — saw combined sales drop 33% from copycat competition. Amgen is outrunning its own product erosion, but the margin for error shrinks if newer launches plateau.
Raised Guidance Sends a Confidence Signal
Management now expects full-year revenue of $38.2–$39.4 billion, up from $37.1–$38.5 billion, and adjusted EPS of $22.30–$23.50, versus the prior $21.70–$23.10.
Both ranges sit above the Street's $37.8 billion revenue consensus.
BMO Capital Markets and Oppenheimer lifted their price targets to $450 with bullish ratings , though Morgan Stanley, Wells Fargo, and others raised targets too but kept neutral or negative ratings — a split verdict that suggests some analysts still see valuation risk.
Cash Is Surging, but So Is Debt
Free cash flow more than doubled to $3.5 billion, up from $1.9 billion a year ago , and the board hiked the quarterly dividend 6% to $2.52 per share. Yet debt outstanding climbed to $57.3 billion, up from $54.6 billion at year-end 2025. That leverage — a legacy of the Horizon Therapeutics acquisition — means Amgen must keep growing just to service its obligations comfortably. The quarter proves the growth engine is firing; the question is whether it can stay hot long enough to shrink a balance sheet that dwarfs most peers.